ACTUATE THERAPEUTICS INC. - COMMON STOCK

Actuate Therapeutics Reports Positive Follow-Up Data from its Randomized Controlled Phase 2 Trial Demonstrating Extended Long-Term Overall Survival Benefit with Elraglusib Plus Chemotherapy for Metastatic Pancreatic Cancer in Oral Presentation at ASCO GI 2026

12 Jan 2026 08:45:00 By Nasdaq GlobeNewswire

Actuate Therapeutics Announces Positive Patient Outcomes from Phase 1 Trial in Difficult-to-Treat Refractory Pediatric Cancers

06 Jan 2026 08:45:00 By Nasdaq GlobeNewswire

Actuate Therapeutics Phase 2 Metastatic Pancreatic Cancer Data Selected for Oral and Poster Presentation at ASCO GI 2026

18 Dec 2025 08:45:00 By Nasdaq GlobeNewswire

Actuate Therapeutics Announces Publication of Positive Phase II Clinical Data for Elraglusib Combined with Platinum Chemotherapy and Sequential Immunotherapy in Recurrent, Metastatic Salivary Gland Carcinoma

15 Dec 2025 08:45:00 By Nasdaq GlobeNewswire

Actuate Therapeutics Provides FDA with Updated Clinical Data Package to Support Planned Regulatory Interactions with FDA and EMA Over the Coming Months

22 Sep 2025 08:45:00 By Nasdaq GlobeNewswire

Actuate Therapeutics Announces Closing of $17.25 Million Public Offering of Common Stock, Including Full Exercise of Over-Allotment Option

11 Sep 2025 16:01:00 By Nasdaq GlobeNewswire

Actuate Therapeutics Announces Pricing of $15.0 Million Public Offering of Common Stock

10 Sep 2025 08:31:02 By Nasdaq GlobeNewswire

Actuate Therapeutics Announces Proposed Public Offering of Common Stock

09 Sep 2025 16:07:09 By Nasdaq GlobeNewswire

Actuate Therapeutics To Collaborate with Incyte Corporation and the University of Pittsburgh on Clinical Trial of Elraglusib in Combination with Retifanlimab and mFOLFIRINOX in Patients with Advanced Pancreatic Cancer

06 Aug 2025 08:45:00 By Nasdaq GlobeNewswire

Actuate Therapeutics Advances Clinical Program in Ewing Sarcoma After Positive Phase 1 Trial Demonstrates Complete and Partial Responses in Difficult-to-Treat Pediatric Sarcomas

17 Jul 2025 08:45:00 By Nasdaq GlobeNewswire

Actuate Therapeutics Highlights Significant and Sustained Survival Benefit in Key Metastatic Pancreatic Cancer Patient Populations in Phase 2 Elraglusib Trial

24 Jun 2025 09:15:00 By Nasdaq GlobeNewswire

Actuate Therapeutics Reports Positive Biomarker and Machine Learning Data from Phase 2 Elraglusib Trial in First-Line Treatment of Metastatic Pancreatic Cancer at ASCO

20 Jun 2025 08:45:00 By Nasdaq GlobeNewswire

Actuate Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes

16 Jun 2025 08:30:00 By Nasdaq GlobeNewswire

Actuate Therapeutics Shares Highlights from KOL Event on Positive Topline Elraglusib Phase 2 Data in First-Line Treatment of Metastatic Pancreatic Cancer

02 Jun 2025 09:00:00 By Nasdaq GlobeNewswire

Actuate Therapeutics Presents Topline Elraglusib Phase 2 Data at ASCO 2025 Annual Meeting: Trial Meets Primary Endpoint of Median Overall Survival and Doubles 1-Year Survival in First-Line Treatment of Metastatic Pancreatic Cancer

31 May 2025 16:30:00 By Nasdaq GlobeNewswire

Actuate Therapeutics Announces Details for 2025 ASCO Annual Meeting Presentation on Topline Elraglusib Phase 2 Data in First-Line Treatment of Metastatic Pancreatic Cancer

22 May 2025 17:05:00 By Nasdaq GlobeNewswire

Actuate Therapeutics to Host KOL Event on Topline Phase 2 Data of Elraglusib in Metastatic Pancreatic Ductal Adenocarcinoma During ASCO Annual Meeting

07 May 2025 08:00:01 By Nasdaq GlobeNewswire

Actuate Therapeutics Announces Statistically Significant Topline Results from Global Phase 2 Trial of Elraglusib in First-Line Treatment of Metastatic Pancreatic Cancer

06 May 2025 08:00:01 By Nasdaq GlobeNewswire

Actuate Therapeutics to Participate in Citizens Life Sciences Conference 2025

30 Apr 2025 08:00:00 By Nasdaq GlobeNewswire

Actuate to Present Elraglusib Phase 2 Topline Data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

23 Apr 2025 10:24:10 By Nasdaq GlobeNewswire